EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques

Lars Pache, John K Bui, Lindsay M Klouser, Christine M Fennessey, Alexander C Noyola, Teresa Einhaus, Haiying Zhu, Laurence Stensland, Isai Leguizamo, Abubakarr A Koroma, Peter Teriete, W L William Chang und 14 weitere

Journal of Clinical Investigation · 16.03.2026 · 136 (6)

DOI: 10.1172/jci187961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.03.2026. Verfasst von Lars Pache und 25 weiteren Autor:innen. Beteiligte Einrichtung: Center for Therapeutics Discovery, NCI Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA. Hauptthemen laut MEDLINE: Simian Immunodeficiency Virus, Virus Latency, Simian Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the success of antiretroviral therapy in controlling HIV replication, latent viral reservoirs persist, presenting a major barrier to a cure. Current treatment approaches that aim to reactivate latent virus and eliminate infected cells, termed “shock and kill,” hold promise but have yet to demonstrate meaningful reservoir reduction in vivo. In this study, we explored combining ciapavir, a Smac mimetic latency-reversing agent, with adeno-associated virus–delivered (AAV-delivered) eCD4-Ig to treat antiretroviral therapy–suppressed, SHIV-infected rhesus macaques. We could demonstrate that a Smac mimetic can induce modest reactivation of the latent SHIV reservoir, as evidenced by transient increases in plasma viremia. However, while AAV-expressed eCD4-Ig conferred partial protection against intrarectal SHIV challenge in uninfected animals, neither eCD4-Ig nor ciapavir reduced the viral reservoir in SHIV-infected rhesus macaques, as determined by total SHIV DNA and a 5-target intact provirus detection assay. Animals treated with the combination showed no significant differences in viral rebound kinetics post–analytical treatment interruption compared with controls. Additionally, repeated ciapavir dosing resulted in adverse effects in some animals, suggesting potential toxicity with repeat administration. These findings highlight the challenges in reducing viral reservoirs using this shock-and-kill approach, particularly in SHIV-infected models, and suggest that further optimization of both latency-reversing agent and immune-mediated clearance strategies is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Simian Immunodeficiency VirusVirus LatencySimian Acquired Immunodeficiency SyndromeAnimalsMacaca mulattaDependovirusHumans

Stichwörter der Autor:innen

AIDS/HIVDrug therapyInfectious diseaseVirology

Autor:innen und Institutionen

  • Center for Therapeutics Discovery, NCI Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
  • Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine and.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NIDA NIH HHS
  • NIMH NIH HHS
  • NIH/NIAID
  • NIH/NIDA
  • NIH/NIMH
  • NIH/ORIP

Zitieren

APA

Pache, L., Bui, J. K., Klouser, L. M., Fennessey, C. M., Noyola, A. C., Einhaus, T., Zhu, H., Stensland, L., Leguizamo, I., Koroma, A. A., Teriete, P., Chang, W. L. W., Hyrien, O., Duggan, N. N., Heimann, D., Pérez-Osorio, A. C., Bar, K. J., Cosford, N. D., Keele, B. F., …, & Peterson, C. W. (2026). Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques. Journal of Clinical Investigation, 136(6). https://doi.org/10.1172/jci187961

Vancouver

Pache L, Bui JK, Klouser LM, Fennessey CM, Noyola AC, Einhaus T, et al. Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques. Journal of Clinical Investigation. 2026;136(6). doi:10.1172/jci187961

BibTeX
@article{Pache2026,
  author = {Pache, Lars and Bui, John K and Klouser, Lindsay M and Fennessey, Christine M and Noyola, Alexander C and Einhaus, Teresa and Zhu, Haiying and Stensland, Laurence and Leguizamo, Isai and Koroma, Abubakarr A and Teriete, Peter and Chang, W L William and Hyrien, Ollivier and Duggan, Natasha N and Heimann, Dominik and Pérez-Osorio, Ailyn C and Bar, Katharine J and Cosford, Nicholas Dp and Keele, Brandon F and Hartigan-O'Connor, Dennis J and Farzan, Michael and Gardner, Matthew R and Jerome, Keith R and Chanda, Sumit K and Kiem, Hans-Peter and Peterson, Christopher W},
  title = {Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {6},
  doi = {10.1172/jci187961}
}
Kostenlos starten →